Pay in 4 interest-free payments of $6.35 Learn more
Ships within 48 hours · Estimated delivery Oct 29 - Nov 3
Adverse reactions should be reported to the MHRA via the Yellow Card Scheme
Critical for assessing sarcopenic obesity in older adults on GLP-1 therapy
An 8-week trial of supervised weight reduction with low-energy diet showed a mean weight loss of 14.2 kg, and significant improvement was observed in individuals in the intervention group in forced expiratory volume at one second (FEV1), forced vital capacity (FVC), dyspnea, use of rescue medication, and number of exacerbations, compared with controls [42]
works for up to 1012 years
Respiratory Very common (10% or more): Nasopharyngitis (up to 14.5%) Common (1% to 10%): Sinusitis, influenza GLP-1 receptor agonists: Postmarketing reports : Pulmonary aspiration Rare cases of pulmonary aspiration have occurred in patients receiving GLP-1 receptor agonists undergoing elective surgeries/procedures requiring general anesthesia or deep sedation
US$ 22.36
US$ 26.41
US$ 23.36
